According to @StockMKTNewz, CNBC reports that Eli Lilly (LLY) is in talks with the Trump administration to provide discounted drugs to consumers through the new TrumpRx direct-to-consumer website, with discussions ongoing per CNBC.

According to @business, Novo Nordisk shares rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly’s older drug Trulicity in a real-world survey of certain U.S. patients; source: Bloomberg, link: https://www.bloomberg.com/news/articles/2025-09-18/novo-rises-after-ozempic-beats-older-lilly-drug-in-survey. The survey outcome was cited as the catalyst for the session’s move, highlighting trading momentum in Novo Nordisk equity on the comparative effectiveness theme; source: Bloomberg. The report did not cite any direct impact on the cryptocurrency market; source: Bloomberg.

According to @StockMKTNewz, citing CNBC, Eli Lilly (LLY) will invest $5 billion to build a manufacturing facility in Virginia to expand production capacity for targeted cancer drugs and other treatments (source: @StockMKTNewz; CNBC). Per @StockMKTNewz’s post referencing CNBC, the announcement outlines a $5 billion capital expenditure focused on scaling output, with no additional timing or financial guidance included in the source post (source: @StockMKTNewz; CNBC). The source post did not reference any direct cryptocurrency market impact (source: @StockMKTNewz).

According to @QCompounding, Eli Lilly (LLY) has a 27.1% return on invested capital (ROIC) (source: @QCompounding). @QCompounding states the company is known for treatments in diabetes, cancer, and obesity and is growing fast thanks to new blockbuster drugs, identifying these therapies as the primary growth drivers (source: @QCompounding). The source does not mention any direct impact on the crypto market (source: @QCompounding).